المؤلفون: Koelmeyer R., Nim H.T., Nikpour M., Sun Y.B., Kao A., Guenther O., Morand E., Hoi A.

مصطلحات الفهرس: SLEDAI, social status, systemic lupus erythematosus/dt [Drug Therapy], autoantibody/ec [Endogenous Compound], azathioprine/dt [Drug Therapy], beta2 glycoprotein 1 antibody/ec [Endogenous Compound], cardiolipin antibody/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], double stranded DNA antibody/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], La antibody/ec [Endogenous Compound], leflunomide/dt [Drug Therapy], lupus anticoagulant/ec [Endogenous Compound], mercaptopurine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rheumatoid factor/ec [Endogenous Compound], ribonucleoprotein antibody/ec [Endogenous Compound], Sm antibody/ec [Endogenous Compound], high disease activity status, adult, article, clinical feature, clinical outcome, comparative study, corticosteroid therapy, demography, disease activity, disease activity score, disease severity, female, human, major clinical study, male, middle aged, observational study, physician, priority journal, scoring system, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29232
Click here for full text options
LibKey Link

المؤلفون: Proudman S., Ferdowsi N., Hill C., Roddy J., Walker J., Nikpour M., Morrisroe K., Hansen D., Huq M., Stevens W., Sahhar J., Ngian G.-S.

مصطلحات الفهرس: breast cancer, cancer incidence, cancer mortality, cancer patient, cancer risk, cancer survival, cohort analysis, controlled study, disease burden, female, health care cost, health care utilization, hematologic malignancy, human, lung cancer, major clinical study, malignant neoplasm/dt [Drug Therapy], melanoma, proportional hazards model, prospective study, risk factor, standardized incidence ratio, systemic sclerosis/di [Diagnosis], systemic sclerosis/dm [Disease Management], systemic sclerosis/dt [Drug Therapy], treatment outcome, abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], DNA directed RNA polymerase III/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], rituximab/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], male, adult, article, Australian, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28980
Arthritis Care and Research
Click here for full text options
LibKey Link

المؤلفون: Antony A., Connelly K., De Silva T., Eades L., Tillett W., Morand E., Ayoub S.

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085
Arthritis Care and Research
Click here for full text options
LibKey Link

المؤلفون: Koelmeyer R., Nim H.T., Nikpour M., Sun Y.B., Kao A., Guenther O., Morand E., Hoi A.

مصطلحات الفهرس: SLEDAI, social status, systemic lupus erythematosus/dt [Drug Therapy], autoantibody/ec [Endogenous Compound], azathioprine/dt [Drug Therapy], beta2 glycoprotein 1 antibody/ec [Endogenous Compound], cardiolipin antibody/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], double stranded DNA antibody/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], La antibody/ec [Endogenous Compound], leflunomide/dt [Drug Therapy], lupus anticoagulant/ec [Endogenous Compound], mercaptopurine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rheumatoid factor/ec [Endogenous Compound], ribonucleoprotein antibody/ec [Endogenous Compound], Sm antibody/ec [Endogenous Compound], high disease activity status, adult, article, clinical feature, clinical outcome, comparative study, corticosteroid therapy, demography, disease activity, disease activity score, disease severity, female, human, major clinical study, male, middle aged, observational study, physician, priority journal, scoring system, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29232
Lupus Science and Medicine
LibKey Link

المؤلفون: Proudman S., Ferdowsi N., Hill C., Roddy J., Walker J., Nikpour M., Morrisroe K., Hansen D., Huq M., Stevens W., Sahhar J., Ngian G.-S.

مصطلحات الفهرس: breast cancer, cancer incidence, cancer mortality, cancer patient, cancer risk, cancer survival, cohort analysis, controlled study, disease burden, female, health care cost, health care utilization, hematologic malignancy, human, lung cancer, major clinical study, malignant neoplasm/dt [Drug Therapy], melanoma, proportional hazards model, prospective study, risk factor, standardized incidence ratio, systemic sclerosis/di [Diagnosis], systemic sclerosis/dm [Disease Management], systemic sclerosis/dt [Drug Therapy], treatment outcome, abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], DNA directed RNA polymerase III/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], rituximab/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], male, adult, article, Australian, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28980
Arthritis Care and Research
LibKey Link

المؤلفون: Antony A., Connelly K., De Silva T., Eades L., Tillett W., Morand E., Ayoub S.

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085
Arthritis Care and Research
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Rabusa C., Ferdowsi N., Nikpour M., Proudman S., Morrisroe K., Hill C., Stevens W., Sahhar J., Ngian G.-S.

مصطلحات الفهرس: abatacept/pe [Pharmacoeconomics], ambrisentan/dt [Drug Therapy], ambrisentan/pe [Pharmacoeconomics], angiotensin receptor antagonist/dt [Drug Therapy], angiotensin receptor antagonist/pe [Pharmacoeconomics], antiarrhythmic agent/dt [Drug Therapy], antiarrhythmic agent/pe [Pharmacoeconomics], antibiotic agent/dt [Drug Therapy], antibiotic agent/pe [Pharmacoeconomics], antilipemic agent/dt [Drug Therapy], antilipemic agent/pe [Pharmacoeconomics], azathioprine/dt [Drug Therapy], azathioprine/pe [Pharmacoeconomics], beta adrenergic receptor blocking agent/dt [Drug Therapy], beta adrenergic receptor blocking agent/pe [Pharmacoeconomics], bosentan/dt [Drug Therapy], bosentan/pe [Pharmacoeconomics], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/pe [Pharmacoeconomics], cyclosporin/dt [Drug Therapy], cyclosporin/pe [Pharmacoeconomics], dipeptidyl carboxypeptidase inhibitor/pe [Pharmacoeconomics], diuretic agent/dt [Drug Therapy], diuretic agent/pe [Pharmacoeconomics], histamine H2 receptor antagonist/dt [Drug Therapy], histamine H2 receptor antagonist/pe [Pharmacoeconomics], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pe [Pharmacoeconomics], iloprost/dt [Drug Therapy], iloprost/pe [Pharmacoeconomics], leflunomide/dt [Drug Therapy], leflunomide/pe [Pharmacoeconomics], macitentan/dt [Drug Therapy], macitentan/pe [Pharmacoeconomics], methotrexate/dt [Drug Therapy], methotrexate/pe [Pharmacoeconomics], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/pe [Pharmacoeconomics], penicillamine/dt [Drug Therapy], penicillamine/pe [Pharmacoeconomics], prednisolone/dt [Drug Therapy], prednisolone/pe [Pharmacoeconomics], prostacyclin/pe [Pharmacoeconomics], proton pump inhibitor/dt [Drug Therapy], proton pump inhibitor/pe [Pharmacoeconomics], rituximab/dt [Drug Therapy], rituximab/pe [Pharmacoeconomics], sildenafil/dt [Drug Therapy], sildenafil/pe [Pharmacoeconomics], tadalafil/dt [Drug Therapy], tadalafil/pe [Pharmacoeconomics], tocilizumab/dt [Drug Therapy], tocilizumab/pe [Pharmacoeconomics], tumor necrosis factor inhibitor/dt [Drug Therapy], tumor necrosis factor inhibitor/pe [Pharmacoeconomics], unindexed drug, prostacyclin/dt [Drug Therapy], ambulatory care, article, Australia, cardiovascular disease/dt [Drug Therapy], data analysis, drug cost, economic aspect, emergency care, gastrointestinal disease/dt [Drug Therapy], health care cost, health care utilization, hospital patient, hospitalization cost, human, prevalence, priority journal, pulmonary hypertension/dt [Drug Therapy], quantitative analysis, systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38696
Medicine
Click here for full text options
LibKey Link

المؤلفون: Rabusa C., Ferdowsi N., Nikpour M., Proudman S., Morrisroe K., Hill C., Stevens W., Sahhar J., Ngian G.-S.

مصطلحات الفهرس: abatacept/pe [Pharmacoeconomics], ambrisentan/dt [Drug Therapy], ambrisentan/pe [Pharmacoeconomics], angiotensin receptor antagonist/dt [Drug Therapy], angiotensin receptor antagonist/pe [Pharmacoeconomics], antiarrhythmic agent/dt [Drug Therapy], antiarrhythmic agent/pe [Pharmacoeconomics], antibiotic agent/dt [Drug Therapy], antibiotic agent/pe [Pharmacoeconomics], antilipemic agent/dt [Drug Therapy], antilipemic agent/pe [Pharmacoeconomics], azathioprine/dt [Drug Therapy], azathioprine/pe [Pharmacoeconomics], beta adrenergic receptor blocking agent/dt [Drug Therapy], beta adrenergic receptor blocking agent/pe [Pharmacoeconomics], bosentan/dt [Drug Therapy], bosentan/pe [Pharmacoeconomics], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/pe [Pharmacoeconomics], cyclosporin/dt [Drug Therapy], cyclosporin/pe [Pharmacoeconomics], dipeptidyl carboxypeptidase inhibitor/pe [Pharmacoeconomics], diuretic agent/dt [Drug Therapy], diuretic agent/pe [Pharmacoeconomics], histamine H2 receptor antagonist/dt [Drug Therapy], histamine H2 receptor antagonist/pe [Pharmacoeconomics], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pe [Pharmacoeconomics], iloprost/dt [Drug Therapy], iloprost/pe [Pharmacoeconomics], leflunomide/dt [Drug Therapy], leflunomide/pe [Pharmacoeconomics], macitentan/dt [Drug Therapy], macitentan/pe [Pharmacoeconomics], methotrexate/dt [Drug Therapy], methotrexate/pe [Pharmacoeconomics], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/pe [Pharmacoeconomics], penicillamine/dt [Drug Therapy], penicillamine/pe [Pharmacoeconomics], prednisolone/dt [Drug Therapy], prednisolone/pe [Pharmacoeconomics], prostacyclin/pe [Pharmacoeconomics], proton pump inhibitor/dt [Drug Therapy], proton pump inhibitor/pe [Pharmacoeconomics], rituximab/dt [Drug Therapy], rituximab/pe [Pharmacoeconomics], sildenafil/dt [Drug Therapy], sildenafil/pe [Pharmacoeconomics], tadalafil/dt [Drug Therapy], tadalafil/pe [Pharmacoeconomics], tocilizumab/dt [Drug Therapy], tocilizumab/pe [Pharmacoeconomics], tumor necrosis factor inhibitor/dt [Drug Therapy], tumor necrosis factor inhibitor/pe [Pharmacoeconomics], unindexed drug, prostacyclin/dt [Drug Therapy], ambulatory care, article, Australia, cardiovascular disease/dt [Drug Therapy], data analysis, drug cost, economic aspect, emergency care, gastrointestinal disease/dt [Drug Therapy], health care cost, health care utilization, hospital patient, hospitalization cost, human, prevalence, priority journal, pulmonary hypertension/dt [Drug Therapy], quantitative analysis, systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38696
Medicine
Click here for full text options
LibKey Link

المؤلفون: Esposito J., Proudman S.M., Walker J., Roddy J., Zochling J., Rabusa C., Sahhar J., Stevens W., Brown Z., Nikpour M.

مصطلحات الفهرس: complement component C3/ec [Endogenous Compound], CD20 antibody/dt [Drug Therapy], calcineurin inhibitor/dt [Drug Therapy], azathioprine/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], serology, scoring system, polymyositis, practice guideline, prediction, adult, antibody detection, article, body mass, clinical feature, cohort analysis, complement deficiency, connective tissue disease, controlled study, demography, disease activity, disease association, disease severity, erythrocyte sedimentation rate, female, finger ulcer, gastrointestinal reflux/dt [Drug Therapy], human, major clinical study, male, abatacept/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], penicillamine/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], proton pump inhibitor/dt [Drug Therapy], ribonucleoprotein antibody/ec [Endogenous Compound], Ro antibody/ec [Endogenous Compound], Sm antibody/ec [Endogenous Compound], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], European Scleroderma Study Group disease activity score, prospective study, multicenter study (topic), patient information, complement component C4/ec [Endogenous Compound], rheumatology, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39756
Arthritis Research and Therapy
Click here for full text options
LibKey Link

المؤلفون: Esposito J., Proudman S.M., Walker J., Roddy J., Zochling J., Rabusa C., Sahhar J., Stevens W., Brown Z., Nikpour M.

مصطلحات الفهرس: complement component C3/ec [Endogenous Compound], CD20 antibody/dt [Drug Therapy], calcineurin inhibitor/dt [Drug Therapy], azathioprine/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], serology, scoring system, polymyositis, practice guideline, prediction, adult, antibody detection, article, body mass, clinical feature, cohort analysis, complement deficiency, connective tissue disease, controlled study, demography, disease activity, disease association, disease severity, erythrocyte sedimentation rate, female, finger ulcer, gastrointestinal reflux/dt [Drug Therapy], human, major clinical study, male, abatacept/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], penicillamine/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], proton pump inhibitor/dt [Drug Therapy], ribonucleoprotein antibody/ec [Endogenous Compound], Ro antibody/ec [Endogenous Compound], Sm antibody/ec [Endogenous Compound], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], European Scleroderma Study Group disease activity score, prospective study, multicenter study (topic), patient information, complement component C4/ec [Endogenous Compound], rheumatology, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39756
Arthritis Research and Therapy
LibKey Link

المؤلفون: Zochling J., Scott J., Bird P., Burnet S., De Jager J., Griffiths H., Tymms K., Nicholls D., Roberts L., Arnold M., Littlejohn G.

مصطلحات الفهرس: gold/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], adult, article, comorbidity, DAS28, disease activity, disease control, disease severity, drug safety, erythrocyte sedimentation rate, female, human, major clinical study, male, middle aged, musculoskeletal pain, remission, rheumatoid arthritis/dt [Drug Therapy], abatacept/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], corticosteroid/po [Oral Drug Administration], disease modifying antirheumatic drug/dt [Drug Therapy], Article

URL: Click here for full text options
LibKey Link

المؤلفون: Zochling J., Scott J., Bird P., Burnet S., De Jager J., Griffiths H., Tymms K., Nicholls D., Roberts L., Arnold M., Littlejohn G.

مصطلحات الفهرس: gold/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], adult, article, comorbidity, DAS28, disease activity, disease control, disease severity, drug safety, erythrocyte sedimentation rate, female, human, major clinical study, male, middle aged, musculoskeletal pain, remission, rheumatoid arthritis/dt [Drug Therapy], abatacept/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], corticosteroid/po [Oral Drug Administration], disease modifying antirheumatic drug/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/42004
Click here for full text options
LibKey Link

المؤلفون: Scott J., Tymms K.E., Zochling J., Littlejohn G., Roberts L., Arnold M., Bird P., Burnet S., de Jager J., Griffiths H., Nicholls D.

مصطلحات الفهرس: rheumatoid arthritis/dt [Drug Therapy], adult, article, Australia, DAS28, disease activity, disease control, disease duration, disease severity, erythrocyte sedimentation rate, female, human, major clinical study, male, multicenter study, observational study, priority journal, remission, disease modifying antirheumatic drug/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], prednisolone/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27479
Click here for full text options
LibKey Link

المؤلفون: Scott J., Tymms K.E., Zochling J., Littlejohn G., Roberts L., Arnold M., Bird P., Burnet S., de Jager J., Griffiths H., Nicholls D.

مصطلحات الفهرس: rheumatoid arthritis/dt [Drug Therapy], adult, article, Australia, DAS28, disease activity, disease control, disease duration, disease severity, erythrocyte sedimentation rate, female, human, major clinical study, male, multicenter study, observational study, priority journal, remission, disease modifying antirheumatic drug/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], prednisolone/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27479
LibKey Link

المؤلفون: Hoi A., Littlejohn G.O.

مصطلحات الفهرس: monotherapy, patient compliance, polypharmacy, priority journal, prospective study, rheumatoid arthritis/dt [Drug Therapy], treatment outcome, alanine aminotransferase/ec [Endogenous Compound], aminotransferase/ec [Endogenous Compound], leflunomide/ae [Adverse Drug Reaction], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], patient monitoring, adult, aminotransferase blood level, article, clinical practice, comorbidity, disease severity, follow up, human, liver function test, liver toxicity/ep [Epidemiology], liver toxicity/si [Side Effect], major clinical study, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32801
Click here for full text options
LibKey Link

المؤلفون: Littlejohn G., Gingold M., Montag K., Boers A.

مصطلحات الفهرس: multicenter study, outpatient department, prescription, tumor necrosis factor inhibitor/dt [Drug Therapy], adult, aged, article, clinical practice, community care, controlled study, disease activity, disease control, drug efficacy, drug tolerability, female, human, major clinical study, male, monotherapy, priority journal, prospective study, rheumatoid arthritis/dt [Drug Therapy], rheumatology, scoring system, abatacept/dt [Drug Therapy], adalimumab/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], disease modifying antirheumatic drug/cb [Drug Combination], disease modifying antirheumatic drug/dt [Drug Therapy], etanercept/dt [Drug Therapy], hydroxychloroquine/cb [Drug Combination], hydroxychloroquine/dt [Drug Therapy], infliximab/dt [Drug Therapy], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], Article

URL: Click here for full text options
LibKey Link

المؤلفون: Hoi A., Littlejohn G.O.

مصطلحات الفهرس: monotherapy, patient compliance, polypharmacy, priority journal, prospective study, rheumatoid arthritis/dt [Drug Therapy], treatment outcome, alanine aminotransferase/ec [Endogenous Compound], aminotransferase/ec [Endogenous Compound], leflunomide/ae [Adverse Drug Reaction], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], patient monitoring, adult, aminotransferase blood level, article, clinical practice, comorbidity, disease severity, follow up, human, liver function test, liver toxicity/ep [Epidemiology], liver toxicity/si [Side Effect], major clinical study, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32801
LibKey Link

المؤلفون: Littlejohn G., Gingold M., Montag K., Boers A.

مصطلحات الفهرس: multicenter study, outpatient department, prescription, tumor necrosis factor inhibitor/dt [Drug Therapy], adult, aged, article, clinical practice, community care, controlled study, disease activity, disease control, drug efficacy, drug tolerability, female, human, major clinical study, male, monotherapy, priority journal, prospective study, rheumatoid arthritis/dt [Drug Therapy], rheumatology, scoring system, abatacept/dt [Drug Therapy], adalimumab/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], disease modifying antirheumatic drug/cb [Drug Combination], disease modifying antirheumatic drug/dt [Drug Therapy], etanercept/dt [Drug Therapy], hydroxychloroquine/cb [Drug Combination], hydroxychloroquine/dt [Drug Therapy], infliximab/dt [Drug Therapy], leflunomide/cb [Drug Combination], leflunomide/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30410
LibKey Link